Antibody-drug conjugate · Cytotoxic, directed at transferrin receptor 1 (CD71) (TFRC) · developed by CytomX Therapeutics
CX-2029 is a probody-drug conjugate made of an anti-CD71 (transferrin receptor 1) antibody masked by a peptide that is cleaved by tumor-associated proteases, linked to the cytotoxic agent MMAE. After unmasking and internalization in CD71-expressing tumor cells, released MMAE binds tubulin and inhibits microtubule polymerization. It is studied in solid tumors, head and neck cancer, non-small cell lung cancer, diffuse large B-cell lymphoma and esophageal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03543813 | Phase 1/2 | Solid Tumor, Adult | Completed | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Large B Cell LymphomaEsophageal CancerHead and Neck CancerNon Small Cell Lung CancerSolid Tumor, Adult
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →